Five Prime Therapeutics to Present at the Barclays Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., March 11, 2016 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX) (Five Prime), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, today announced that Aron Knickerbocker, Executive Vice President and Chief Business Officer, will present at the Barclays Global Healthcare Conference on Thursday, March 17, 2016 at 10:45 AM Eastern Daylight Time.

The live webcast will be accessible at http://investor.fiveprime.com/events.cfm or directly at https://cc.talkpoint.com/barc002/031516a_ae/?entity=133_M336FR1.  Five Prime will maintain an archived replay of the webcast on its website for 30 days after the conference.

About Five Prime

Five Prime Therapeutics, Inc. discovers and develops innovative therapeutics to improve the lives of patients with serious diseases. Five Prime's comprehensive discovery platform, which encompasses virtually every medically relevant extracellular protein, positions it to explore pathways in cancer, inflammation and their intersection in immuno-oncology, an area with significant therapeutic potential and a growing focus of the company's R&D activities. Five Prime has entered into strategic collaborations with leading global pharmaceutical companies and has promising product candidates in clinical and late preclinical development. For more information, please visit www.fiveprime.com.

CONTACT: CONTACT:

Heather Rowe, Investor Relations 
415-365-5737
heather.rowe@fiveprime.com

Ads

You May Also Like

NewLink Genetics to Host Its Second Quarter 2018 Financial Results Conference Call on July 31, 2018

AMES, Iowa, July 10, 2018 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced that ...

Cellceutix Provides Update on Developing p53 Drug Candidate Kevetrin as an Oral Anti-Cancer Agent

BEVERLY, Mass., March 03, 2017 (GLOBE NEWSWIRE) -- Cellceutix Corporation, (OTCQB:CTIX) (“the Company”), a ...

PIVOTAL TRIAL CONFIRMS LONG-TERM SAFETY AND EFFICACY OF IV IRON DOSING STRATEGY

PIVOTAL TRIAL CONFIRMS LONG-TERM SAFETY AND EFFICACY OF INTRAVENOUS IRON DOSING STRATEGY ALLOWING HIGHER ...